Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/121131

Beta release

Statistics of Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Statistics for this year
PeriodVisitsDownloads
202400
Statistics for the last 3 months
PeriodVisitsDownloads
2024-0900
2024-1000
2024-1100